Video

Combo Therapy vs Insulin: Type 2 Diabetes

The Qatar Study investigated the efficacy of exenatide plus pioglitazone versus basal-bolus insulin in poorly-controlled type 2 diabetes.

The Qatar Study investigated the efficacy of combination therapy with exenatide plus pioglitazone versus basal-bolus insulin.

The study, published in Diabetes Care, randomized 231 patients with poorly controlled type 2 diabetes on a sulfonylurea and metformin to receive either exenatide plus pioglitazone or insulin therapy.

After a mean follow up of 12 months, combination therapy caused a significantly greater decrease in HbA1c vs insulin therapy, dropping from a mean HbA1c of 10 to 6.1%.

In addition, patients in the insulin group had a significantly greater weight gain and more episodes of hypoglycemia.

Related Videos
Rahul Aggarwal, MD | Credit: LinkedIn
Brendon Neuen, MBBS, PhD | Credit: X.com
HCPLive Five at ADA 2024 | Image Credit: HCPLive
Ralph DeFronzo, MD | Credit: UT San Antonio
Timothy Garvey, MD | Credit: University of Alabama at Birmingham
Alexandra Louise Møller, MS, PhD | Credit: LinkedIn
A panel of 5 experts on Cushing's syndrome
A panel of 5 experts on Cushing's syndrome
Optimizing Diabetes Therapies with New Classifications
Vlado Perkovic, MBBS, PhD | Credit: George Institute of Global Health
© 2024 MJH Life Sciences

All rights reserved.